These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
138 related articles for article (PubMed ID: 8718601)
1. Bacterial resistance to fluoroquinolones: mechanisms and patterns. Hooper DC Adv Exp Med Biol; 1995; 390():49-57. PubMed ID: 8718601 [No Abstract] [Full Text] [Related]
2. Epidemiology of quinolone resistance: Europe and North and South America. Goldstein FW; Acar JF Drugs; 1995; 49 Suppl 2():36-42. PubMed ID: 8549361 [TBL] [Abstract][Full Text] [Related]
3. [Fluoroquinolones--a current review]. Christ W; Kemmler H Med Monatsschr Pharm; 2001 Jul; 24(7):215-25. PubMed ID: 11486553 [No Abstract] [Full Text] [Related]
6. Sitafloxacin in the treatment of patients with infections caused by vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus. Shetty N; Wilson AP J Antimicrob Chemother; 2000 Oct; 46(4):633-8. PubMed ID: 11020265 [TBL] [Abstract][Full Text] [Related]
7. Methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci: therapeutic realities and possibilities. Michel M; Gutmann L Lancet; 1997 Jun; 349(9069):1901-6. PubMed ID: 9217771 [TBL] [Abstract][Full Text] [Related]
8. Emerging resistance to fluoroquinolones in staphylococci: an alert. Trucksis M; Hooper DC; Wolfson JS Ann Intern Med; 1991 Mar; 114(5):424-6. PubMed ID: 1992885 [No Abstract] [Full Text] [Related]
9. Resistance among important pathogens and the antimicrobial activity of parenteral fluoroquinolones at 43 US medical centres. Jones RN; Kehrberg EN; Erwin ME Drugs; 1995; 49 Suppl 2():179-81. PubMed ID: 8549295 [No Abstract] [Full Text] [Related]
10. [Fluoroquinolone carboxylic acids: is research on the development of resistance becoming invalidated?]. Wiedemann B; Heisig P Pharm Unserer Zeit; 1993 Nov; 22(5-6):286-95. PubMed ID: 8121930 [No Abstract] [Full Text] [Related]
11. [Efficacy of lomefloxacin and ofloxacin in complex therapy of infections in patients with burns]. Krutikov MG; Alekseev AA; Bobrovnikov AE; Grishina IA; Elagina LV; Izotova GN; Iakovlev VP Antibiot Khimioter; 1998; 43(10):27-31. PubMed ID: 9825107 [TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activity of BAY Y 3118 with other fluoroquinolones. Molinari G; Schito GC Drugs; 1995; 49 Suppl 2():222-5. PubMed ID: 8549310 [No Abstract] [Full Text] [Related]
14. Effectiveness of fluoroquinolones against gram-positive bacteria. Bush K; Goldschmidt R Curr Opin Investig Drugs; 2000 Sep; 1(1):22-30. PubMed ID: 11249591 [TBL] [Abstract][Full Text] [Related]
15. USA resistance patterns among UTI pathogens. Thomson KS; Sanders WE; Sanders CC J Antimicrob Chemother; 1994 May; 33 Suppl A():9-15. PubMed ID: 7928840 [TBL] [Abstract][Full Text] [Related]
16. [Study of the chemotherapeutic effect of sanguinarine]. Vichkanova SA; Rubinchik MA; Adgina VV; Fedorchenko TS Farmakol Toksikol; 1969; 32(3):325-8. PubMed ID: 4309382 [No Abstract] [Full Text] [Related]
17. [Mechanisms for the development of quinolone resistance]. Kojima M Nihon Rinsho; 1997 May; 55(5):1252-60. PubMed ID: 9155183 [TBL] [Abstract][Full Text] [Related]
18. In-vitro activity of DU-6859a against methicillin-resistant Staphylococcus aureus isolates with reduced susceptibilities to vancomycin. Tanaka M; Wada N; Kurosaka SM; Chiba M; Sato K; Hiramatsu K J Antimicrob Chemother; 1998 Oct; 42(4):552-3. PubMed ID: 9818762 [No Abstract] [Full Text] [Related]
19. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance. Entenza JM; Que YA; Vouillamoz J; Glauser MP; Moreillon P Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359 [TBL] [Abstract][Full Text] [Related]